Repositioning Candidate Details
| Candidate ID: | R0162 |
| Source ID: | DB00575 |
| Source Type: | approved |
| Compound Type: | small molecule |
| Compound Name: | Clonidine |
| Synonyms: | |
| Molecular Formula: | C9H9Cl2N3 |
| SMILES: | ClC1=CC=CC(Cl)=C1NC1=NCCN1 |
| Structure: |
|
| DrugBank Description: | Clonidine is an imidazole derivate that acts as an agonist of alpha-2 adrenoceptors.[A180559] This activity is useful for the treatment of hypertension, severe pain, and ADHD.[L7237,L7240,L7243,L7246] Clonidine was granted FDA approval on 3 September 1974.[L7237] |
| CAS Number: | 4205-90-7 |
| Molecular Weight: | 230.094 |
| DrugBank Indication: | Clonidine tablets and transdermal systems are indicated for the treatment of hypertension alone or in combination with other medications.[L7237,L7240] A clonidine injection is indicated for use with opiates in the treatment of severe cancer pain where opiates alone are insufficient.[L7243] An extended release tablet of clonidine is indicated for the treatment of ADHD either alone or in combination with other medications.[L7246] Clonidine is also used for the diagnosis of pheochromocytoma,[A180565] treatment of nicotine dependance,[A180568] and opiate withdrawal.[A180571] |
| DrugBank Pharmacology: | Clonidine functions through agonism of alpha-2 adrenoceptors which have effects such as lowering blood pressure, sedation, and hyperpolarization of nerves.[A180559] It has a long duration of action as it is given twice daily and the therapeutic window is between 0.1mg and 2.4mg daily.[L7237,L7240,L7243,L7246] |
| DrugBank MoA: | Clonidine is primarily an alpha-2 adrenoceptor agonist which causes central hypotensive and anti-arrhythmogenic effects.[A180559] The alpha-2 adrenoceptor is coupled to the G-proteins G<sub>o</sub> and G<sub>i</sub>.[A180559] G<sub>i</sub> inhibits adenylyl cyclase and activates opening of a potassium channel that causes hyperpolarization.[A180559] Clonidine binding to the alpha-2 adrenoceptor causes structural changes in the alpha subunit of the G-protein, reducing its affinity for GDP.[A180559] Magnesium catalyzes the replacement of GDP with GTP.[A180559] The alpha subunit dissociates from the other subunits and associates with an effector.[A180559] The stimulation of alpha-2 adrenoceptors in the locus coeruleus may be responsible for the hypnotic effects of clonidine as this region of the brain helps regulate wakefulness.[A180559] Clonidine can also decrease transmission of pain signals at the spine.[A180559] Finally clonidine can affect regulators of blood pressure in the ventromedial and rostral-ventrolateral areas of the medulla.[A180559] |
| Targets: | Alpha-2B adrenergic receptor; Alpha-2C adrenergic receptor; Alpha-2A adrenergic receptor; Alpha-1A adrenergic receptor; Alpha-1B adrenergic receptor; Alpha-1D adrenergic receptor |
| Inclusion Criteria: |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I02 | 1184 | nephrotic syndrome | "A nephrosis characterized by marked increase in glomerular protein permeability resulting in marked elevation of urine protein levels, hypoalbuminemia, hyperlipidemia, and hypercoagulability." [url:https\://en.wikipedia.org/wiki/Nephrotic_syndrome, url:https\://www.niddk.nih.gov/health-information/kidney-disease/nephrotic-syndrome-adults] | Details |